Department of Bone and soft tissue Oncology was established in 1979 as the birthplace of bone and soft tissue tumor surgery in China. It is a characteristic specialty of bone and soft tissue tumor with the basic surgical treatment, combined with radiotherapy and chemotherapy, targeted therapy and immunotherapy. 

In 2018, in order to meet the needs of the expansion and development of the department, the original osteochondroma was divided into bone tumor group and soft tissue tumor group. Xing Ruwei served as director of soft tissue tumor group. We have 8 doctors, including 3 doctorates and 2 master's degrees. There are 2 chief physicians, 3 deputy chief physicians, 2 attending doctors, 1 resident, and 1 doctoral supervisor. 

With the joint efforts of general medical staff, a comprehensive treatment model based on surgical treatment of bone and soft tissue tumors and skin tumors was established. The standard surgery, chemotherapy, targeted therapy and immunotherapy for bone tumors, soft tissue tumors and skin tumors, the comprehensive treatment of metastases and the repair and reconstruction of various limb and skin tumors are among the highest in the country.  

On the basis of inheriting the tradition of "barrier resection", the department has carried out a number of new operations characterized by complete resection, functional preservation and reconstruction of bone, soft tissue and skin malignant tumors, including prosthesis replacement after resection of malignant tumors of bone and skin, transfer repair and reconstruction of soft tissue and skin malignant tumors after resection of soft tissue and skin malignant tumors, to meet the new characteristics of tumor incidence and the new needs of tumor patients. Reconstruction of pedicle screw and prosthesis after resection of spinal and pelvic tumors. At present, neoadjuvant radiotherapy and chemotherapy combined with postoperative adjuvant radiotherapy and chemotherapy, targeted therapy, immunotherapy and other treatment of refractory bone and soft tissue malignant tumors and achieve limb salvage and prolonged survival has become the routine treatment in our department. A number of new clinical techniques have been developed, including the application of 3D printing model in the treatment of bone and soft tissue tumors, the biomechanical analysis of the plantar after reconstruction of malignant tumors of foot and ankle, and so on. In order to standardize and improve the therapeutic safety and prolong the survival time of patients with sarcomas, a number of drug clinical studies have been carried out, and related sci papers have been published. In recent years, he has undertaken 2 projects of international cooperation, 3 of the National Natural Science Foundation of China, 2 of Tianjin Science and Technology Commission, 1 of Tianjin Education Commission and 2 at hospital level. Our department has deeply studied the genomics, transformation medicine and accurate treatment of sarcomas and malignant melanoma. It is in the leading international advanced position in osteosarcoma, leiomyosarcoma, malignant peripheral schwannoma and so on. It is in the advanced position of clinical cancer research,molecular in the field of osteosarcoma, leiomyosarcoma, malignant peripheral schwannoma and so on.

Our Team
Ruwei Xing M.D.